Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines

Oncology (Switzerland)

Volumn 53, Issue 4, 1996, Pages 327-333

  Ohsaki, Yoshinobu ^a   Ishida, Sakae ^a   Fujikane, Toshiaki ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cisplatin; Cultured cells; Etoposide; Lung cancer; Pentoxifylline; Xanthine derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; COLONY FORMING CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETOPOSIDE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PENTOXIFYLLINE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0029994862     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227582     Document Type: Article

References (21)

1. Klastersky J: Therapy of small cell lung cancer: Anything new? Eur J Cancer Clin Oncol 1988; 24:107-112.
2. Lucke-Huhlc C: Alpha-irradiation-induced G; delay: A period of cell recovery', Radiat Res 1982:89:298-308.
3. Trosko JE, Frank P, Chu EHY, Becker JE: Caffeine inhibition of post-replication repair of N-acctoxy-2-acetylaminofluorene-damagcd DNA in Chinese hamster cells, Cancer Res 1973:33: 2444-2449.
4. Ishida R, Kozaki M, Takahashi T: Caffeine alone causes DNA damage in Chinese hamster ovary cells, Cell Struct Funct 1985; 10:405-409.
5. Lau CC, Pardee AB: Mechanism by which caffeine potentiates lethality of nitrogen mustard, Proc Natl Acad Sei USA 1982:79:2942-2946.
6. Dougherty JB, Kelsen D, Kemeny N, Magill G, Botet J, Niedzwieki D: Advanced pancreatic cancer: A phase I-II trial of cisplatin, high dose cytarabinc and caffeine, J Natl Cancer Inst 1989:81:1735-1738.
7. Rail TW: Central nervous system stimulants, The methylxanthincs; in Gilman AG, Goodman LS, Rail TW, Murad F (eds): The Pharmacological Basis of Therapeutics, ed 7. New York, Macmillan, 1985. pp 589-603.
8. Fingert IIJ, Chang JD, Pardee AB: Cytotoxic, cell cycle, and chromosomal effects of methyl-xanthines in human tumor cells treated with alkylating agents, Cancer Res 1986:46:2463-2467.
9. Fingert HJ, Pu AT, Chen Z, Googe PB, Alley MC, Pardee AB: In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa, Cancer Res 1988:48:4375-4381.
10. Mumane JP, Byfield JE, Ward JF, Calabro-Jones P: Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents, Nature 1980:285:326-329.
11. Allen TE, Aliano NA, Cowan RJ, Grigg GW, Hart NK, Lamberton JA, Lane A: Amplification of antitumor activity of phleomycins and bleomycins in rats and mice by caffeine, Cancer Res 1985:45:2516-2521.
12. Waldrcn CA, Rasko I: Caffeine enhancement of X-ray killing in cultured human and rodent cells, Radiat Res 1978;73:95-110.
13. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells, Science 1977:197: 461-463.
14. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemothera-py: The concept of additivity, Int J Radiat Oncol Biol Phys 1979:5:85-95
15. Chou T-C: The median-effect principle and the combination index for quantitation of synergism and antagonism; in Chou T-C, Rideout DC (eds): Synergism and Antagonism in Chemotherapy, San Diego, Academic Press, 1991. pp 61-102.
16. Dolbeare F, Grantzner H, Pallavicini M, Gray JW: Flow' cytometric measurement of total DNA content and incorporated bromodeoxy-uridine, Proc Natl Acad Sci USA 1983:80: 5573-5577.
17. Zwelling LA, Kohn KW: Mechanism of action of cisdichlorodiammincplatinum (II), Cancer Treat Rep 1979:63:1439-1444.
18. Ross W, Rowe T, Glisson B, Yalowich J, Lin L: RoleoftopoisomcrascII in mediatingepipodo-phylotoxin-induccd DNA cleavage, Cancer Res 1984:44:5857-5860.
19. Minocha A, Long BH: Inhibition of the DNA catenation activity of type II topoisomerase by VPI6-213 and VM26. Biochem Biophys Res Commun 1984:122:165-170.
20. Wartcrs RL, Lyons BW, Kennedy K, Li M: Topoisomerase activity in irradiated mammalian cells, Mutat Res 1989:216:43-55.
21. Smith RV, Waller ES, Doluisio JT, Bauza MT, Puri SK, Ho I, Lassman HB: Pharmacokinetics of orally administered pentoxifylline in humans, J Pharm Sci 1986:75:47-52.